PDCD1 and neoplasm: Therefore, the addition of PD-1/PD-L1 blocking mAb to an existing treatment regimen shows encouraging promise in boosting anti-tumor and anti-viral responses by several immune cell types, including NK cells, through counteracting a potent mechanism of immune evasion.